|
|
| Undisclosed anti-L1CAM ADC / CIS Pharma (0 Trials) |
|
| Undisclosed anti-LAG3 mAb / Protheragen (0 Trials) |
|
| Undisclosed anti-MICA/B antibody / BMS (0 Trials) |
|
| Undisclosed anti-MSLN/CD3 BiTE / Amgen (0 Trials) |
|
| Undisclosed anti-MUC1-Ab / Protheragen (0 Trials) |
|
| Undisclosed anti-Nectin-4-ATI020 ADC / Anwita Biosci (0 Trials) |
|
| Undisclosed anti-PAR2 mAb / Nxera Pharma (0 Trials) |
|
| Undisclosed anti-PD-1 antibody / Premier Biomedical (0 Trials) |
|
| Undisclosed anti-PD-1 vaccine / Immunovo (0 Trials) |
|
| Undisclosed anti-PD-L1 antibody / Tikcro Technologies (0 Trials) |
|
| Undisclosed anti-PD1 monoclonal antibody / Novartis (0 Trials) |
|
| Undisclosed anti-tau misfolding small molecule therapeutic / Takeda (0 Trials) |
|
| Undisclosed anti-TIM3 mAbs / Trellis Biosci (0 Trials) |
|
| Undisclosed anti-WISP-1 antibody therapeutic / Sorrento (0 Trials) |
|
| Undisclosed antibody therapies / Hanwha Solutions (0 Trials) |
|
| Undisclosed anticancer therapeutic / Aqilion (0 Trials) |
|
| Undisclosed anticancer therapeutic / Arvinas (0 Trials) |
|
| Undisclosed anticancer therapeutic / Amyloid Solution, UPPTHERA (0 Trials) |
|
| Undisclosed antiviral therapeutic / Institut Pasteur (0 Trials) |
|
| Undisclosed antiviral therapeutic / Sirona Biochem (0 Trials) |
|
| Undisclosed antiviral therapeutic / Dominari Holdings, University of Maryland (0 Trials) |
|
| Undisclosed antiviral therapeutic / Agricultural Biotechnology Research Center (0 Trials) |
|
| Undisclosed antiviral therapeutic / A2A Pharma, Laxai Life Sci (0 Trials) |
|
| Undisclosed antiviral therapeutic / Medivir, SciLifeLab (0 Trials) |
|
| Undisclosed antiviral therapy / UCLA (0 Trials) |
|
| Undisclosed APOE4 structure modulator / Escape Bio (0 Trials) |
|
| Undisclosed apoptosis stimulators / (0 Trials) |
|
| Undisclosed AR degrader / Kintor Pharma (0 Trials) |
|
| Undisclosed AR peptide therapeutic / Acomhal Research (0 Trials) |
|
| Undisclosed AR TRN modulator / Kronos Bio (0 Trials) |
|
| Undisclosed AR-V7 targeting PROTAC degrader / Novartis (0 Trials) |
|
| Undisclosed ARID1B degrader / Foghorn Therap (0 Trials) |
|
| Undisclosed ASO based cancer therapeutic / BIORCHESTRA (0 Trials) |
|
| Undisclosed ASO based epilepsy therapeutic / SK Bio, BIORCHESTRA (0 Trials) |
|
| Undisclosed ASO-based cancer therapeutic / Vanda, Olipass (0 Trials) |
|
| Undisclosed ATAD2 inhibitor / Lupin (0 Trials) |
|
| Undisclosed atopic dermatitis therapeutic / Almirall, Evotec (0 Trials) |
|
| Undisclosed ATR inhibitor / Easton Biopharma (0 Trials) |
|
| Undisclosed autophagy-based degrader / Casma Therap (0 Trials) |
|
| Undisclosed avSialidase armed VV / Ansun Biopharma (0 Trials) |
|
| Undisclosed B7-H3 ADC therapeutic / IntoCell (0 Trials) |
|
| Undisclosed B7-H3-targeted GADLEN / Shattuck (0 Trials) |
|
| Undisclosed B7-H3xNKG2D NKE / Xencor (0 Trials) |
|
| Undisclosed B7-H6 targeted γδ CAR T / Adicet Bio (0 Trials) |
|
| Undisclosed Bax/Bak inhibitor / Amylyx, Sunnybrook Research Institute (0 Trials) |
|
| Undisclosed BCMA CAR-NK / Pregene Biotech (0 Trials) |
|
| Undisclosed BCMA NKE / BMS (0 Trials) |
|
| Undisclosed BCR-ABL inhibitor / Concentra Biosci (0 Trials) |
|
| Undisclosed beta-thalassemia small molecule therapeutic / PharmaEssentia (0 Trials) |
|
| Undisclosed Bi-epitopic therapeutic / AFFiRiS (0 Trials) |
|
| Undisclosed biological therapeutic / Chinese PLA General Hospital (0 Trials) |
|
| Undisclosed bispecific antibody / Rondo Therap (0 Trials) |
|
| Undisclosed c-MET inhibitor / Biocad (0 Trials) |
|
| Undisclosed C5 inhibitor / UCB (0 Trials) |
|
| Undisclosed CAB-HER2-CAR-T / BioAtla, Exuma Biotech (0 Trials) |
|
| Undisclosed cancer therapeutic / Altay Therap (0 Trials) |
|
| Undisclosed cancer therapeutic / Repare Therap, BMS (0 Trials) |
|
| Undisclosed cancer therapeutic / Cyclenium (0 Trials) |
|
| Undisclosed cancer therapeutic / Scorpion Therap, AstraZeneca (0 Trials) |
|
| Undisclosed cancer therapeutic / Engitix (0 Trials) |
|
| Undisclosed cancer therapeutic / Remix Therap, J&J (0 Trials) |
|
| Undisclosed cancer therapeutic / Recursion Pharma (0 Trials) |
|
| Undisclosed cancer therapeutic / Sanofi, IGM Biosciences (0 Trials) |
|
| Undisclosed cancer therapeutic / BiomX (0 Trials) |
|
| Undisclosed cancer therapeutic / Tegmine (0 Trials) |
|
| Undisclosed cancer therapeutic / DepYmed (0 Trials) |
|
| Undisclosed cancer therapeutic / Enlaza (0 Trials) |
|
| Undisclosed cancer therapeutic / 3T Biosci, Boehringer Ingelheim (0 Trials) |
|
| Undisclosed cancer therapeutic / Aethon Therap (0 Trials) |
|
| Undisclosed cancer therapeutic / AbbVie, Immunome (0 Trials) |
|
| Undisclosed cancer vaccine / Prime Vector Technologies (0 Trials) |
|
| Undisclosed cancer vaccine / RNACure Biopharma (0 Trials) |
|
| Undisclosed candidate #4 / Immunocore (0 Trials) |
|
| Undisclosed CAR Cells / Eureka Therap, Memorial Sloan-Kettering Cancer Center, BMS (0 Trials) |
|
| Undisclosed CAR-NK therapies for solid tumors / Catamaran Bio (0 Trials) |
|
| Undisclosed CAR-NK therapy / Ansun Biopharma (0 Trials) |
|
| Undisclosed CAR-T / Capstan Therap (0 Trials) |
|
| Undisclosed CAR-T adjuvant therapeutic / MPC Therap (0 Trials) |
|
| Undisclosed CAR-T cell therapy / Atara, Memorial Sloan-Kettering Cancer Center (0 Trials) |
|
| Undisclosed CAR-T cell therapy / Inceptor Bio (0 Trials) |
|
| Undisclosed CAR-T cell therapy / Gilead (0 Trials) |
|
| Undisclosed CAR-T cell therapy / RNACure Biopharma (0 Trials) |
|
| Undisclosed CAR-γδT / Pell Bio-Med Techno (0 Trials) |
|
| Undisclosed cardiomyopathy therapeutic / Maze Therap (0 Trials) |
|
| Undisclosed CB1 antagonist / Vyripharm (0 Trials) |
|
| Undisclosed CB2 agonist / Corbus Pharma (0 Trials) |
|
| Undisclosed CBP protein degrader / Foghorn Therap (0 Trials) |
|
| Undisclosed CBP/P300 degrader / SK Bio (0 Trials) |
|
| Undisclosed CBP/P300 degrader / Dr. Reddy’s (0 Trials) |
|
| Undisclosed CCNE1 degrader / FogPharma (0 Trials) |
|
| Undisclosed CCRL2 antagonist / Oxagen (0 Trials) |
|
| Undisclosed CCRL2 modulator therapeutic / Omeros (0 Trials) |
|
| Undisclosed CD117 targeting ETB / Molecular Templates (0 Trials) |
|
| Undisclosed CD137 mAb / BioInvent, Cancer Research UK (0 Trials) |
|
| Undisclosed CD25 chimeric aptamer / Aptamer Sci (0 Trials) |
|
| Undisclosed CD276/CD47-targeted ADC / UAB University - Birmingham (0 Trials) |
|
| Undisclosed CD3 TCB / CytomX, Astellas (0 Trials) |
|
| Undisclosed CD39 targeting ASO / Secarna (0 Trials) |
|
| Undisclosed CD3xBCMA-bsAb / Protheragen (0 Trials) |
|
| Undisclosed CD3XCD20 bsAb / Protheragen (0 Trials) |
|
| Undisclosed CD40 agonist / IcanoMAB (0 Trials) |
|
| Undisclosed CD47 inhibitor / Liminatus (0 Trials) |
|
| Undisclosed CD47 x guide arm 3 bispecific antibody / Virtuoso Therap (0 Trials) |
|
| Undisclosed CD73 inhibitor / Palobiofarma (0 Trials) |
|
| Undisclosed CD73 targeting ASO / Secarna (0 Trials) |
|
| Undisclosed CD73-A2AR dual inhibitor / Dr. Reddy’s (0 Trials) |
|
| Undisclosed CD73/CD39 inhibitor / Ryvu Therap (0 Trials) |
|
| Undisclosed CDH3XCD3 BsAb therapeutic / Amgen (0 Trials) |
|
| Undisclosed CDK1 inhibitor / Carna Biosci (0 Trials) |
|
| Undisclosed CDK11 inhibitor / Syros (0 Trials) |
|
| Undisclosed CDK12 inhibitor / Syros (0 Trials) |
|
| Undisclosed CDK12 inhibitor / Dr. Reddy’s, Exelixis (0 Trials) |
|
| Undisclosed CDK12/13 inhibitor / Lead Discovery Center (0 Trials) |
|
| Undisclosed CDK2 degrader / Plexium (0 Trials) |
|
| Undisclosed CDK2-Cyclin E precision therapeutic / Bayer (0 Trials) |
|
| Undisclosed CDK2/4/6 degrader / BioTheryX (0 Trials) |
|
| Undisclosed CDK2/4/6 inhibitor / Fosun Pharma (0 Trials) |
|
| Undisclosed CDK4/6 inhibitor / CS Group (0 Trials) |
|
| Undisclosed CDK6 inhibitor / Lead Discovery Center (0 Trials) |
|
| Undisclosed CDK7 inhibitor / Beta Pharma (0 Trials) |
|
| Undisclosed CDK8 inhibitor / Insilico Medicine (0 Trials) |
|
| Undisclosed CDK9 degrader / Oncodesign (0 Trials) |
|
| Undisclosed celiac disease therapeutic / Mozart Therap (0 Trials) |
|
| Undisclosed cGAS inhibitor / National Institute of Allergy and Infectious Diseases, Bellbrook Therap (0 Trials) |
|
| Undisclosed cGAS inhibitors / Novartis (0 Trials) |
|
| Undisclosed cGAS/STING pathway inhibitor / Novartis (0 Trials) |
|
| Undisclosed CHAMP / Ranok Therap, Pfizer (0 Trials) |
|
| Undisclosed CHK1 inhibitor / Fosun Pharma (0 Trials) |
|
| Undisclosed circular RNA-based therapeutic / Esperovax, Ginkgo Bioworks (0 Trials) |
|
| Undisclosed CISH inactivated TIL / Intima Biosci, University of Minnesota (0 Trials) |
|
| Undisclosed CK1a/GSPT1 dual degrader / Pin Therap (0 Trials) |
|
| Undisclosed CK1α activator / Exelixis, StemSynergy Therap (0 Trials) |
|
| Undisclosed Claudin 18.2/CD3 BsAb / Antibody Therap (0 Trials) |
|
| Undisclosed CLDN18.2 ADC / Integral Molecular (0 Trials) |
|
| Undisclosed CLEC-1 mAbs / OSE Immunotherapeutics (0 Trials) |
|
| Undisclosed CLEC12A TriKE / GT Biopharma (0 Trials) |
|
| Undisclosed CLK kinase inhibitor / Redona Therap (0 Trials) |
|
| Undisclosed CML therapy / PinotBio (0 Trials) |
|
| Undisclosed CNS disorder therapeutic / Sumitomo Pharma, Carna Biosci (0 Trials) |
|
| Undisclosed colorectal cancer targeted therapy / EdiGene, Beijing Cancer Hospital (0 Trials) |
|
| Undisclosed complement 1s inhibitor for CNS diseases / UCB (0 Trials) |
|
| Undisclosed COPD therapeutic / Surrozen (0 Trials) |
|
| Undisclosed coronavirus therapeutic / Theragen Etex (0 Trials) |
|
| Undisclosed coronavirus therapeutic / Korea National Institutes of Health (0 Trials) |
|
| Undisclosed COVID-19 therapeutic / Southwest Research Institute (0 Trials) |
|
| Undisclosed COVID-19 therapeutic / Kainos Medicine (0 Trials) |
|
| Undisclosed COVID-19 therapeutic / Collaborations Pharma (0 Trials) |
|
| Undisclosed CRC therapeutic / Servier, AbbVie (0 Trials) |
|
| Undisclosed CRISPR/Cas9 gene editing therapeutic / Sarepta Therap, Duke University (0 Trials) |
|
| Undisclosed Crohn's disease therapeutic / MPC Therap (0 Trials) |
|
| Undisclosed CSF-1R inhibitor / BCI Pharma, Mithra (0 Trials) |
|
| Undisclosed CTLA-4 antagonist / Lanier Biotherap (0 Trials) |
|
| Undisclosed CTLA-4 X mono-IL-10 ADAPTIR multi-specific therapeutic / Aptevo Therap (0 Trials) |
|
| Undisclosed CTLA4 immuno-oncology / Olipass (0 Trials) |
|
| Undisclosed CTLA4 inhibitor antibody therapeutic / Tikcro Technologies (0 Trials) |
|
| Undisclosed CyclinA/Cdk2 interaction inhibitor / Circle Pharma (0 Trials) |
|
| Undisclosed cystic fibrosis therapeutic / Vertex (0 Trials) |
|
| Undisclosed cystic fibrosis therapeutic / Gensaic (0 Trials) |
|
| Undisclosed cytokine derivative therapeutic / Sutro Biopharma (0 Trials) |
|
| Undisclosed dermatologic / Eli Lilly (0 Trials) |
|
| Undisclosed DMD therapeutic / CANbridge Pharma (0 Trials) |
|
| Undisclosed DNA damage target 1 therapeutic / Ideaya Biosci (0 Trials) |
|
| Undisclosed DNA damage target 2 therapeutic / Ideaya Biosci (0 Trials) |
|
| Undisclosed DNA methyltransferase inhibitor / Metheor Therapeutics (0 Trials) |
|
| Undisclosed DsiRNA targeting HIF2a / Novo Nordisk (0 Trials) |
|
| Undisclosed dual Aβ/ tau oligomer inhibitor / Treventis Corp (0 Trials) |
|
| Undisclosed dual HIF-1/HIF-2 inhibitor / Curve Therap (0 Trials) |
|
| Undisclosed dual WEE1/PKMYT1 inhibitor / Roivant (0 Trials) |
|
| Undisclosed DUB inhibitor / AbbVie (0 Trials) |
|
| Undisclosed DXR-inhibitor / Basilea, Boston University (0 Trials) |
|
| Undisclosed EGFR based B cell immunotherapy / Imugene (0 Trials) |
|
| Undisclosed EGFR inhibitor / SpringWorks Therap, Dana-Farber Cancer Institute (0 Trials) |
|
| Undisclosed EGFR/B7H3 CAR-T / Hedy Group, Guangzhou Medical University (0 Trials) |
|
| Undisclosed EGFRvIII targeted ApDC / PinotBio, Aptamer Sci (0 Trials) |
|
| Undisclosed eIF4E inhibitor / Pfizer, eFFECTOR Therap (0 Trials) |
|
| Undisclosed epilepsy therapeutic / AgoneX Biopharma (0 Trials) |
|
| Undisclosed epilepsy therapeutic / XWPharma (0 Trials) |
|
| Undisclosed epilepsy therapeutic / Taysha Gene Therapies (0 Trials) |
|
| Undisclosed epilepsy therapeutic / Neurelis (0 Trials) |
|
| Undisclosed epilepsy therapeutic / Theracule (0 Trials) |
|
| Undisclosed epilepsy therapeutic / Shanghai SIMR Biotech (0 Trials) |
|
| Undisclosed etiotropic preparation / Federal Medical Biological Agency (0 Trials) |
|
| Undisclosed factor H therapeutic / Eleva (0 Trials) |
|
| Undisclosed FANCM inhibitor / ALT Therap (0 Trials) |
|
| Undisclosed fatty acid amide hydrolase inhibitor / Maruishi Pharma (0 Trials) |
|
| Undisclosed FGF-1 Parkinson therapeutic / Zhittya Genesis Medicine (0 Trials) |
|
| Undisclosed FGFR2/3 inhibitor / Oscotec (0 Trials) |
|
| Undisclosed FGFR4 inhibitor / Tyra Biosci (0 Trials) |
|
| Undisclosed fibroblast activation protein (FAP)-targeted radiopharmaceutical / Navigo Proteins, ITM Isotopen Technologien Munchen (0 Trials) |
|
| Undisclosed follow-up compound for Alzheimer's Disease / CuroNZ (0 Trials) |
|
| Undisclosed follow-up compound for depression / CuroNZ (0 Trials) |
|
| Undisclosed FOXA1 inhibitor therapeutic / Curve Therap (0 Trials) |
|
| Undisclosed FXIa Inhibitor / University of California, Pfizer (0 Trials) |
|
| Undisclosed GBA1 gene therapy / Voyager, Neurocrine (0 Trials) |
|
| Undisclosed GBM therapeutic / Origenis, Memorial Sloan-Kettering Cancer Center (0 Trials) |
|
| Undisclosed GBM therapeutic / Ridgeline Therap (0 Trials) |
|
| Undisclosed GBM therapeutic / Divide & Conquer (0 Trials) |
|
| Undisclosed GBM therapeutic / Sentinel Oncology (0 Trials) |
|
| Undisclosed GBM therapeutic / Modifi Bio (0 Trials) |
|
| Undisclosed gene therapy / CANbridge Pharma (0 Trials) |
|
|